Payment overview · 2025
General Payments
$402.68
24 reported records · 5 companies
Healthcare provider profile · identity verified
Donald T Eagle, MD
Allopathic & Osteopathic Physicians|Family Medicine · EUSTIS, FL · NPI 1326086760
Verified facts
What the public records show
CMS Open Payments records show Donald T Eagle, MD received $402.68 in general payments during 2025 across 24 reported records.
Amgen Inc. accounted for 60.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $243.86 | 60.6% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.38 | 14.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.74 | 10.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.42 | 10.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.28 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $402.68 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $243.86 | 16 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $167.66 | 15 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.42 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.73 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.51 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 992 | 356 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 783 | 270 |
| Lisinopril | Lisinopril | 744 | 254 |
| Levothyroxine Sodium | Levothyroxine Sodium | 670 | 228 |
| Amlodipine Besylate | Amlodipine Besylate | 608 | 215 |
| Metformin Hcl | Metformin Hcl | 465 | 171 |
| Omeprazole | Omeprazole | 389 | 145 |
| Metoprolol Tartrate | Metoprolol Tartrate | 363 | 121 |
| Losartan Potassium | Losartan Potassium | 346 | 122 |
| Pioglitazone Hcl | Pioglitazone Hcl | 315 | 116 |
| Methylprednisolone | Methylprednisolone | 287 | 234 |
| Simvastatin | Simvastatin | 279 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 269 | 104 |
| Meloxicam | Meloxicam | 268 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 81 |
| Gabapentin | Gabapentin | 237 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 91 |
| Azithromycin | Azithromycin | 217 | 181 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 66 |
| Allopurinol | Allopurinol | 194 | 59 |
| Montelukast Sodium | Montelukast Sodium | 193 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 185 | 58 |
| Furosemide | Furosemide | 184 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 67 |
| Ezetimibe | Ezetimibe | 173 | 69 |
| Eliquis | Apixaban | 160 | 54 |
| Potassium Chloride | Potassium Chloride | 157 | 59 |
| Alprazolam | Alprazolam | 145 | 38 |
| Prednisone | Prednisone | 142 | 83 |
| Sertraline Hcl | Sertraline Hcl | 131 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 43 |
| Carvedilol | Carvedilol | 121 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 120 | 86 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 34 |
| Trazodone Hcl | Trazodone Hcl | 107 | 33 |
| Alendronate Sodium | Alendronate Sodium | 106 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 51 |
| Famotidine | Famotidine | 92 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 31 |
| Atenolol | Atenolol | 88 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 86 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 23 |
| Glimepiride | Glimepiride | 82 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 23 |
| Glipizide | Glipizide | 76 | 28 |
| Celecoxib | Celecoxib | 73 | 26 |
| Buspirone Hcl | Buspirone Hcl | 72 | 26 |
| Lorazepam | Lorazepam | 71 | 15 |
| Clonidine Hcl | Clonidine Hcl | 69 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 25 |
| Metformin Hcl Er | Metformin Hcl | 66 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 25 |
| Temazepam | Temazepam | 64 | 18 |
| Donepezil Hcl | Donepezil Hcl | 60 | 19 |
| Januvia | Sitagliptin Phosphate | 60 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 59 | 18 |
| Ibuprofen | Ibuprofen | 57 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 20 |
| Finasteride | Finasteride | 55 | 16 |
| Synthroid | Levothyroxine Sodium | 54 | 21 |
| Xarelto | Rivaroxaban | 52 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 23 |
| Fenofibrate | Fenofibrate | 47 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 18 |
| Clonazepam | Clonazepam | 43 | 11 |
| Enalapril Maleate | Enalapril Maleate | 43 | 12 |
| Pregabalin | Pregabalin | 42 | 17 |
| Tramadol Hcl | Tramadol Hcl | 41 | 30 |
| Valsartan | Valsartan | 40 | 17 |
| Memantine Hcl | Memantine Hcl | 39 | 19 |
| Spironolactone | Spironolactone | 39 | 17 |
| Jardiance | Empagliflozin | 38 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | 13 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Topiramate | Topiramate | 34 | 12 |
| Benazepril Hcl | Benazepril Hcl | 33 | 12 |
| Estradiol | Estradiol | 33 | 13 |
| Fluconazole | Fluconazole | 33 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 33 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | 20 |
| Bupropion Xl | Bupropion Hcl | 31 | 12 |
| Fenofibrate | Fenofibrate,micronized | 31 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | 12 |
| Diazepam | Diazepam | 28 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 13 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Jantoven | Warfarin Sodium | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | 12 |
| Ramipril | Ramipril | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 13 |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Klor-Con 10 | Potassium Chloride | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 14 |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 12 |
| Nystatin | Nystatin | 19 | 12 |
| Primidone | Primidone | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 13 |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Ursodiol | Ursodiol | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $402.68 · 24 records | Amgen Inc. | AIRSUPRA, AREXVY, FARXIGA, Korlym, MOUNJARO, OTEZLA, REPATHA, SHINGRIX, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error